Targeting PCSK9 for hypercholesterolemia

QR Code

Targeting PCSK9 for hypercholesterolemia

Dyslipidemias are a predominant risk factor for cardiovascular disease. Biological and genetic research has led to the identification of several genes and proteins that may be pharmacologically targeted to improve lipoprotein profiles and possibly cardiovascular outcomes in patients with dyslipidemi...

Full description

Bibliographic Details
Main Authors:	Norata, Giuseppe, Tibolla, G., Catapano, A.
Format:	Journal Article
Published:	2014
Online Access:	http://hdl.handle.net/20.500.11937/56217

Similar Items

PCSK9 inhibition for the treatment of hypercholesterolemia: Promises and emerging challenges
by: Norata, Giuseppe, et al.
Published: (2014)

Anti-PCSK9 antibodies for the treatment of heterozygous familial hypercholesterolemia: Patient selection and perspectives
by: Catapano, A., et al.
Published: (2017)

Proprotein convertase subtilisin/kexin type 9 (PCSK9): From structure-function relation to therapeutic inhibition
by: Tibolla, G., et al.
Published: (2011)

PCSK9 inhibitors and dyslipidemia: The clinical evidence
by: Norata, Giuseppe
Published: (2014)

PCSK9 inhibition in statin-intolerant HeFH patients: What's new?
by: Casula, M., et al.
Published: (2017)

Proprotein Convertase Subtilisin-Kexin type-9 (PCSK9) and triglyceride-rich lipoprotein metabolism: Facts and gaps
by: Baragetti, A., et al.
Published: (2018)

PCSK9 deficiency results in increased ectopic fat accumulation in experimental models and in humans
by: Baragetti, A., et al.
Published: (2017)

New therapeutic principles for familial hypercholesterolemia
by: Norata, Giuseppe
Published: (2014)

Effect of treatment with pravastatin or ezetimibe on endothelial function in patients with moderate hypercholesterolemia
by: Grigore, L., et al.
Published: (2013)

Squaring up the health economics of PCSK9 monoclonal antibodies ‘down under’
by: Watts, G., et al.
Published: (2018)

Statins and skeletal muscles toxicity: From clinical trials to everyday practice
by: Norata, Giuseppe, et al.
Published: (2014)

Gene silencing approaches for the management of dyslipidaemia
by: Norata, Giuseppe, et al.
Published: (2013)

Targeting Cholesterol in Non-ischemic Heart Failure: A Role for LDLR Gene Therapy?
by: Catapano, A., et al.
Published: (2017)

In vivo and in vitro effects of phaleria macrocarpa (scheff.) boerl on low density lipoprotein and pcsk9 expression
by: Chong, Soo Ching
Published: (2011)

HDL: To treat or not to treat?
by: Pirillo, A., et al.
Published: (2014)

Biology of proprotein convertase subtilisin kexin 9: Beyond low-density lipoprotein cholesterol lowering
by: Norata, Giuseppe, et al.
Published: (2016)

Phaleria macrocarpa (Scheff.) Boerl fruit aqueous extract enhances LDL receptor and PCSK9 expression in vivo and in vitro.
by: Chong, Soo Ching, et al.
Published: (2011)

Association Of Single Nucleotide Polymorphisms (Snp) In Pcsk9 Gene With Lipid Analysis Among Iban And Bidayuh Ethnic Groups In Sarawak Population.
by: H. H., Hood, et al.
Published: (2015)

Statins and periodontal inflammation: A pleiotropic effect of statins or a pleiotropic effect of LDL-cholesterol lowering?
by: Norata, Giuseppe, et al.
Published: (2014)

Leonurine: A new comer in the natural compounds affecting atherosclerosis
by: Norata, Giuseppe, et al.
Published: (2012)

HDL and adaptive immunity: A tale of lipid rafts
by: Norata, Giuseppe, et al.
Published: (2012)

Challenges in the health economics of familial hypercholesterolemia
by: Norman, Richard, et al.
Published: (2016)

PCSK9 inhibitory activity of marine-derived compounds, aaptaminoids, and benzamide originated from Aaptos aaptos and Acanthaster planci as a potential treatment for atherosclerosis.
by: Habsah, Mohamad, et al.
Published: (2020)

The CD1d-natural killer T cell axis in atherosclerosis
by: Bondarenko, S., et al.
Published: (2014)

Translating the microRNA signature of microvesicles derived from human coronary artery smooth muscle cells in patients with familial hypercholesterolemia and coronary artery disease
by: de Gonzalo-Calvo, D., et al.
Published: (2017)

Postprandial lipemia as a cardiometabolic risk factor
by: Pirillo, A., et al.
Published: (2014)

Novel concepts in HDL pharmacology
by: Remaley, A., et al.
Published: (2014)

High-density lipoprotein subfractions - What the clinicians need to know
by: Pirillo, A., et al.
Published: (2013)

Vascular inflammation and low-density lipoproteins: Is cholesterol the link? A lesson from the clinical trials
by: Catapano, A., et al.
Published: (2017)

Therapy and clinical trials: Aggressive statin therapy versus combined and emerging approaches
by: Catapano, A., et al.
Published: (2011)

Niemann-pick C1-like 1 (NPC1L1) inhibition and cardiovascular diseases
by: Pirillo, A., et al.
Published: (2016)

LOX-1, OxLDL, and atherosclerosis
by: Pirillo, A., et al.
Published: (2013)

HDLs, immunity, and atherosclerosis
by: Norata, Giuseppe, et al.
Published: (2011)

Treating high density lipoprotein cholesterol (HDL-C): Quantity versus quality
by: Pirillo, A., et al.
Published: (2013)

HDL in infectious diseases and sepsis
by: Pirillo, A., et al.
Published: (2015)

Strategies for the use of nonstatin therapies
by: Pirillo, A., et al.
Published: (2017)

New therapeutic principles in dyslipidaemia: Focus on LDL and Lp(a) lowering drugs
by: Norata, Giuseppe, et al.
Published: (2013)

High density lipoproteins and atherosclerosis: Emerging aspects
by: Sala, F., et al.
Published: (2012)

Apolipoprotein C-III: From Pathophysiology to Pharmacology
by: Norata, Giuseppe, et al.
Published: (2015)

HEALTH LITERACY IN FAMILIAL HYPERCHOLESTEROLEMIA: A CROSS-NATIONAL STUDY
by: Hagger, Martin, et al.
Published: (2018)

Cannot write session to /tmp/vufind_sessions/sess_j05b9ub2rmrablae275p98fr6d